drugset / Trial / NCT05511766
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2024-04-25
- Completion
- 2025-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allopurinol | Small molecule | 300 mg | Oral |
| Comparator | Atorvastatin | Small molecule | 20 mg | Oral |